Navigation Links
Breakthrough opens new avenues for hep C vaccine

Hopes for an effective vaccine and treatment against the potentially fatal hepatitis C virus (HCV) have received a major boost following the discovery of two 'Achilles' heels' within the virus.

A team of medical researchers from the University of New South Wales (UNSW) studied individuals at high risk of HCV infection, including a number identified within a few weeks of the onset of infection.

Using a new technique called next generation deep sequencing and sophisticated computer analytics the team, led by Professor Andrew Lloyd and Associate Professor Peter White, were able to identify the 'founder' virus responsible for the initial infection and then track changes within the virus as it was targeted by the immune system.

"We discovered that hepatitis C has not one but two 'Achilles' heels' that provide opportunities for vaccine development," said Dr Fabio Luciani, from UNSW's Inflammation and Infection Research Centre and the research team's biostatistician.

"If we can help the immune system to attack the virus at these weak points early on, then we could eliminate the infection in the body completely," he said.

A paper describing the breakthrough appears in the leading scientific journal in the field of virology, PLoS Pathogens.

Hepatitis C virus infection is a global pandemic with more than 120 million people infected worldwide, including some 200,000 Australians. The virus causes progressive liver disease leading to cirrhosis, liver failure and cancer. Current antiviral treatments are arduous, costly, and only partially effective.

Team member and virologist Dr Rowena Bull said the discovery of the weakest links meant vaccine researchers could now focus their attentions on the most likely avenues for success.

"The first weak point was identified at transmission, when the virus has to survive the transfer from one individual to another," Dr Bull said.

"The second weakness, and surprise finding, was the significant drop in the diversity of the viral variants in each individual studied, occurring about three months after transmission, around the time where the immune system is starting to combat the virus. A lower number of variants means the virus is easier to target."

Study leader Professor Lloyd said the discoveries were significant because of their potential to overcome longstanding barriers to hepatitis C vaccine development.

"To date hepatitis C has been difficult to target with single interventions because there are many different strains of the virus," he said. "In addition, like HIV, the hepatitis C virus mutates very rapidly and exists as a complex family of mutated viruses within every infected individual, meaning the virus can avoid efforts by the immune system to keep it under control," Professor Lloyd said.

"What's more, a third of infected people can have an effective immune response that eliminates the virus early on. This means key initial immune responses were difficult to identify and study because early infection and elimination can go unrecognised."

Professor Lloyd said work is now underway to identify the key immunological features of the founder viruses in order to guide new vaccines.

"Further research will test the extent of the immune response against these founder viruses in a cohort of very early infected individuals," he said.


Contact: Professor Andrew Lloyd
University of New South Wales

Related medicine news :

1. Breakthrough in genetics of fibroids
2. Major ALS breakthrough
3. Researchers capture breakthrough data on cervical spine injuries
4. CT scans unleash a breakthrough in catching early stage lung cancer
5. NEJM study: New drug represents breakthrough in treatment of hepatitis C
6. Breakthrough in the search for new treatments for MS
7. A scientific breakthrough at the IRCM could help understand certain cancers
8. New research provides breakthrough in understanding common cancer
9. Breakthrough medical food reverses risk of heart disease and diabetes
10. Research breakthrough on male infertility
11. Huntingtons disease breakthrough equals hope for patients
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent ... sharing, the 2016 Building Better Radiology Marketing Programs meeting will showcase ... Sunday, March 6, 2016, at Caesars Palace in Las Vegas with a pre-conference ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment ... itself for not only fulfilling the needs of advisers and clients but going ... price and providing top-tier customer service. However, there's always room for improvement, which ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... largest, most successful and prominent nonprofit healthcare organizations in the country. They have ... with various organizations, and helped advance the healthcare industry as a whole through ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., ... the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 ... brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive not ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... real-time eReferral system for diagnostic imaging in the Waterloo region. Using the Ocean ... Nuclear Medicine tests directly from their electronic medical record (EMR) without the need ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 26, 2015  The total global healthcare industry ... over 2015-2016. Latin America has the ... , (excluding Japan ), is second with ... continues to face increased healthcare expenditure. In 2013-2014, total government ... from 43.5% in 2008-2009 to 41.2% in 2013-2014. In real ...
(Date:11/25/2015)... N.C. , Nov. 25, 2015 ... the planned investment of at least $15.8  Million ... Wilmington, NC . The expansion ... capacity to meet the growing demands of the ... site expansion will provide up to ...
(Date:11/25/2015)... AVIV, Israel , November 25, 2015 ... (NASDAQ: KTOV ) (TASE: KTOV), a biopharmaceutical company ... simultaneous treatment of various clinical conditions, today announced the ... 3,158,900 American Depository Shares ( ADSs ), each representing ... purchase up to 3,158,900 ADSs. The ADSs and warrants ...
Breaking Medicine Technology: